FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4238827845> ?p ?o ?g. }

• W4238827845 endingPage "53" @default.
• W4238827845 startingPage "51" @default.
• W4238827845 abstract "Take home messages Most side effects of tyrosine kinase inhibitors (TKIs) are reversible and transient, but not necessarily negligible. Nilotinib and Ponatinib are very efficacious, but associated with potentially irreversible cardiovascular events, and selection of suitable patients and preventive intervention for these TKIs is key. Dasatinib is associated with pleural effusion which may occur after many years of drug exposure. Treat patients efficacy oriented in the early disease phase, and if good responses are achieved one should adopt a more quality-of-life-oriented approach. Introduction Chronic myeloid leukemia (CML) patients have excellent prospects to achieve a good response and tolerability with tyrosine kinase inhibitor (TKI) treatment. Independently of which TKI is selected, roughly 5% of patients experience progression, which is difficult to treat.1▪ Reassuringly, about 95% will have a normal life span with similar quality of life (QoL).2 Upon start of TKI treatment, several aspects are of importance for choice of TKI. Factors such as comorbidities, reimbursement situation, age, QoL, risk score, and the prospect of operational cure (treatment-free remission) may influence choice.1▪ By experience, about 30% to 40% of patients need to switch TKI due to tolerability problems or poor response.3▪ Side effects of TKIs are mostly mild and reversible, but with longer follow-up some potentially problematic and a few irreversible toxicities have been identified. Cross-intolerance for nonhematological side effects is unusual, that is, the next TKI may be better tolerated than the first. In Europe, we may use imatinib (IM), nilotinib (NIL), dasatinib (DAS), and bosutinib (BOS) in first line and ponatinib in third and later lines, and I will highlight differences and special features of these TKIs. I highly recommend European LeukemiaNet's review of TKI toxicity by Steegman et al.4▪▪ Current state of the art Communal side effects of TKIs Early hematological toxicity is very common and is probably caused by desired depletion of tumor cells with a poor Ph negative hematopoietic compensatory reserve.5 Hematological toxicity is more common in advanced and late chronic phase, but properties of the drugs also influence. NIL has least toxicity. NIL < IM < DAS = BOS < PON. Some patients have long-term lower hematological indices during treatment, notably also late-onset macrocytic anemia with high mean corpuscular volume/mean corpuscular hemoglobin in older patients. Hematological toxicity grade 3 lasting more than 2 to 3 months is a warning of a problematic treatment course and poor response.6 Treatment with growth factors is encouraged to avoid pausing TKI. In practice, short pauses and dose reductions are sometimes necessary (Fig. 1).Figure 1: Summary of main points on safety of different tyrosine kinase inhibitors available in first-line treatment. AMI = myocardial infarction, DM2 = diabetes type 2, GI = gastrointestinal, PAOD = peripheral arterial occlusive disease, PCI = percutaneous coronary intervention, QoL = quality of life.Tumor lysis Surprisingly rare in CML. Patients should drink up to 3 L on a daily basis the first weeks. Allopurinol is not indicated. Rash Maculopapular or papulosquamous rash is common with all drugs, most notably NIL. Manage with topical steroids, peroral corticosteroids, and dose interruption. Often the rash does not recur upon rechallenge. If so, a switch of TKI may be considered. Fluid retention states Orbital edema is very frequent with IM. Patients should be prewarned about this expected side effect. Excessive lacrimation is frequent. General edema is most common with IM. Gastrointestinal Diarrhea, abdominal pain, constipation, vomiting, and nausea are frequent. BOS gives very frequent short-term diarrhea which should be proactively managed with loperamide. IM and BOS give most GI problems, NIL and DAS less. To avoid GI problems, BOS and IM should be taken with the largest meal. DAS is meal independent, whereas NIL must be taken in a fasting routine. Liver and pancreas Moderate transaminase or pancreatic elevations are not uncommon with TKI treatment. Occurs rarely in DAS and IM treatment, more with NIL, PON, and BOS. This is often transient. Headache Most frequent with DAS and NIL but occurs with all drugs. Musculoskeletal Ill-defined pains are common with all drugs, with highest frequency for IM. Bothersome cramps are very common with IM. Gentle stretching exercises, quinine or magnesium supplement may be attempted. Cardiac QT prolongation is noted, but the practical consequence is unclear. Potentially irreversible toxicity Serositis Most frequently pleural effusions (PEs), but rarely also pericarditis occurs. PE is a troublesome and unpredictable side effect, which may occur years into the treatment course. PE occurs in up to 30% of DAS-treated patients long-term. An incidence of approximately 5% is found with BOS, much rarer for other TKIs. PE is associated with age and may indicate too high dose.7▪ Interruption is recommended, and resolution of PE takes weeks. Pausing is not adverse for efficacy. Some use corticosteroids and diuretics symptomatically, but effect is moderate. Many patients enjoy excellent responses and symptomatic improvement with reinitiation of TKI in lower doses, and anecdotally doses as low as 20 mg daily may still be effective with good tolerability. Recurrence of PE is not infrequent. Fortunately, PE is mostly reversible. Atherothrombotic and metabolic complications In the ENESTnd trial, a clear increase of cardiovascular events was noted for NIL versus IM.8▪ Amputations due to accelerated limb atherosclerosis, cerebrovascular, and coronary events were noted. Events most frequently occurred in older patients with metabolic syndrome or preexisting atherosclerosis, but also in patients without known predisposition. The effect was clearly dose-dependent. No increase in mortality has been detected, but this serious and potentially irreversible morbidity has prompted study of cause and recommendations for prevention. NIL and PON adversely change the lipid status and glucose tolerance/diabetes type II. I carefully evaluate cardiovascular risk with risk scores like qRISK and intervene with nonsmoking orders, treat hypertension, hyperlipidemia diabetes type II and give life style advice. Patients who are elderly, have metabolic syndrome, or manifest atherosclerotic disease are not good candidates for NIL. PON gives an even higher incidence of atherothrombosis than NIL and has similar effects on metabolic parameters.9 PON also raises blood pressure and aggressive treatment (2–3 drugs) is frequently needed. In practice, the only treatment alternative to PON is often allogeneic transplantation, with inherent serious toxicity.10 Hence, vascular disease prevention is key if PON is used and patients may enjoy good treatment effect and QoL in a difficult clinical situation. Renal Reduction in glomerular filtration has been noted by long-term use of IM. Future perspectives General advice for management of side effects by TKIs Side effects are mostly short term and subside with or without symptomatic treatment. Long-term low-grade problems represent a serious threat to efficacy if it affects treatment compliance.11 The patient and doctor treatment alliance is key. Efficacy considerations are most important early in the treatment course, and the patient's risk of progression may influence management of side effects by more aggressive symptomatic treatment versus pausing/dose reduction. If the patient has good efficacy, I am with time more inclined to dose reduce and pause in attempt achieve good QoL. Rule of thumb: Grade 1: No change. Grade 2: side effects may be managed with symptomatic treatment short-term or pausing. Grade 3: pause drug until Gr 1 and reinitiate at original or lower dose. Grade 4: pause, reinitiate at Gr 1 and dose reduce. If side effects subside I try to increase dose at a later stage, particularly if efficacy is not “optimal” according to guidelines." @default.
• W4238827845 created "2022-05-12" @default.
• W4238827845 creator A5062230211 @default.
• W4238827845 date "2019-06-01" @default.
• W4238827845 modified "2023-09-27" @default.
• W4238827845 title "TKI safety" @default.
• W4238827845 cites W2081813128 @default.
• W4238827845 cites W2102999107 @default.
• W4238827845 cites W2158884958 @default.
• W4238827845 cites W2166270808 @default.
• W4238827845 cites W2260921597 @default.
• W4238827845 cites W2343511371 @default.
• W4238827845 cites W2473480037 @default.
• W4238827845 cites W2604410663 @default.
• W4238827845 cites W2763370961 @default.
• W4238827845 cites W2886320425 @default.
• W4238827845 cites W4251009301 @default.
• W4238827845 cites W4294307875 @default.
• W4238827845 doi "https://doi.org/10.1097/hs9.0000000000000200" @default.
• W4238827845 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35309801" @default.
• W4238827845 hasPublicationYear "2019" @default.
• W4238827845 type Work @default.
• W4238827845 citedByCount "0" @default.
• W4238827845 crossrefType "journal-article" @default.
• W4238827845 hasAuthorship W4238827845A5062230211 @default.
• W4238827845 hasBestOaLocation W42388278451 @default.
• W4238827845 hasConcept C144133560 @default.
• W4238827845 hasConceptScore W4238827845C144133560 @default.
• W4238827845 hasIssue "S2" @default.
• W4238827845 hasLocation W42388278451 @default.
• W4238827845 hasLocation W42388278452 @default.
• W4238827845 hasLocation W42388278453 @default.
• W4238827845 hasLocation W42388278454 @default.
• W4238827845 hasLocation W42388278455 @default.
• W4238827845 hasOpenAccess W4238827845 @default.
• W4238827845 hasPrimaryLocation W42388278451 @default.
• W4238827845 hasRelatedWork W1491839574 @default.
• W4238827845 hasRelatedWork W1947684173 @default.
• W4238827845 hasRelatedWork W2586531396 @default.
• W4238827845 hasRelatedWork W2596173151 @default.
• W4238827845 hasRelatedWork W2624733068 @default.
• W4238827845 hasRelatedWork W2765153054 @default.
• W4238827845 hasRelatedWork W2931838652 @default.
• W4238827845 hasRelatedWork W3080576469 @default.
• W4238827845 hasRelatedWork W4231340554 @default.
• W4238827845 hasRelatedWork W2051331738 @default.
• W4238827845 hasVolume "3" @default.
• W4238827845 isParatext "false" @default.
• W4238827845 isRetracted "false" @default.
• W4238827845 workType "article" @default.